Initial and Serial Evaluation of the HF Patient: Difference between revisions
Jump to navigation
Jump to search
Mahmoud Sakr (talk | contribs) (Created page with " |- | bgcolor="LightGreen"|<nowiki>"</nowiki>'''.''' Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in pat...") |
Mahmoud Sakr (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''.''' Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with HF who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''.''' Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with HF who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
Latest revision as of 21:32, 9 August 2013
| Class I |
| ". Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with HF who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. (Level of Evidence: C) " |